e-Drug3D

1947

UPADACITINIB

INN
UPADACITINIB

cas 1310726-60-3

CLASS

IMMUNOMODULATING
A JANUS KINASE (JAK) INHIBITOR
TREATMENT OF RHEUMATOID ARTHRITIS

ROUTE (list)

ORAL

ATC code

L04AF03

PK parameters

Tmax 3 HOUR
PPB 52 PERCENT
t1/2 11 HOUR

Solubility

0.2 TO 38 MILLIGRAM / MILLILITER

Target

TARGET JANUS KINASE (JAK)

DrugCentral

Tyrosine-protein kinase JAK3 UNIPROT P52333 JAK3

Tyrosine-protein kinase JAK1 UNIPROT P23458 JAK1

Download SDF file

1-Pyrrolidinecarboxamide, 3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)-, (3S,4R)-

Formula:
C17H19F3N6O

Calculated chemical properties:

MW 380.38
NB_atoms 27
XLogP 2.91
PSA 70.025
NB_HD 2
NB_HA 7
fsp3 0.47
Lipinski(0=no;1=yes) 1

FDA
NDA 211675 (pdf not found) INN (UPADACITINIB) RINVOQ (ABBVIE) APPROVAL= AP YEAR= 2019
NDA 218347 (pdf not found) INN (UPADACITINIB) RINVOQ LQ (ABBVIE) APPROVAL= AP YEAR= 2024
NDA 218866 (pdf not found) INN (UPADACITINIB) UPADACITINIB (AUROBINDO PHARMA LTD) APPROVAL= TA YEAR= 2025